What is the recommendation for the use of MRAs in people with HFREF?
MRAs should be offered to all people with HFREF, as the evidence indicated a beneficial effect across the disease severity spectrum and is likely to remain cost effective. Furthermore, sacubitril valsartan and ivabradine recommendations were added as possible specialist treatments.